Ikarian Capital, LLC Satsuma Pharmaceuticals, Inc. Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.19 - $7.95 $2.17 Million - $4.11 Million	-517,389 Reduced 79.18%	136,059 $815,000
Q1 2022 May 13, 2022	BUY	$3.78 - $5.32 $90,961 - $128,020	24,064 Added 3.82%	653,448 $2.48 Million
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $66,610 - $105,198	-14,672 Reduced 2.28%	629,384 $2.93 Million
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $154,742 - $233,725	-32,238 Reduced 4.77%	644,056 $4.54 Million
Q1 2021 May 17, 2021	BUY	$4.57 - $7.18 $3.09 Million - $4.86 Million	676,294 New	676,294 $4 Million
Q3 2020 Nov 16, 2020	SELL	$3.85 - $28.47 $1.27 Million - $9.36 Million	-328,824 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.01 - $34.69 $5.26 Million - $11.4 Million	328,824 New	328,824 $9.46 Million

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.